Antihistamines and ovarian cancer survival

nationwide cohort study and in vitro cell viability assay

Freija Verdoodt, Christian Dehlendorff, Marja Jäättelä, Robert Strauss, Anton Pottegård, Jesper Hallas, Søren Friis, Susanne K Kjaer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Antihistamines with cationic amphiphilic drug (CAD) characteristics induce cancer-specific cell death in experimental studies. Epidemiologic evidence is, however, limited. In a Danish nationwide cohort of ovarian cancer patients diagnosed during 2000-2015 (n = 5075), we evaluated the association between antihistamine prescriptions and cancer mortality. We used Cox regression models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for ovarian cancer mortality. In an in vitro cell viability assay, we evaluated cell-death in three ovarian cancer cell lines after treatment with clinically relevant doses of eight antihistamines. In our cohort study, CAD antihistamine use (≥1 prescription; n = 133) was associated with a HR of 0.63 (95% CI: 0.40 to 0.99) compared to use of non-CAD antihistamines (n = 304), and we found a tendencytowards a dose-response association. In our cell viability assay, we found consistent and dose-dependent cytotoxicity for all CAD but not non-CAD antihistamines. In this nationwide cohort study, use of antihistamines with CAD characteristics is associated with a prognostic benefit in ovarian cancer patients.

OriginalsprogEngelsk
TidsskriftNational Cancer Institute. Journal (Print)
ISSN0027-8874
DOI
StatusE-pub ahead of print - 5. nov. 2019

Fingeraftryk

Histamine Antagonists
Ovarian Neoplasms
Cell Survival
Cohort Studies
Pharmaceutical Preparations
Prescriptions
Cell Death
Confidence Intervals
In Vitro Techniques
Proportional Hazards Models
Neoplasms
Cell Line

Citer dette

Verdoodt, Freija ; Dehlendorff, Christian ; Jäättelä, Marja ; Strauss, Robert ; Pottegård, Anton ; Hallas, Jesper ; Friis, Søren ; Kjaer, Susanne K. / Antihistamines and ovarian cancer survival : nationwide cohort study and in vitro cell viability assay. I: National Cancer Institute. Journal (Print). 2019.
@article{3b320236cf6b47cd8fe3475e92437c36,
title = "Antihistamines and ovarian cancer survival: nationwide cohort study and in vitro cell viability assay",
abstract = "Antihistamines with cationic amphiphilic drug (CAD) characteristics induce cancer-specific cell death in experimental studies. Epidemiologic evidence is, however, limited. In a Danish nationwide cohort of ovarian cancer patients diagnosed during 2000-2015 (n = 5075), we evaluated the association between antihistamine prescriptions and cancer mortality. We used Cox regression models to estimate hazard ratios (HRs) with 95{\%} confidence intervals (CIs) for ovarian cancer mortality. In an in vitro cell viability assay, we evaluated cell-death in three ovarian cancer cell lines after treatment with clinically relevant doses of eight antihistamines. In our cohort study, CAD antihistamine use (≥1 prescription; n = 133) was associated with a HR of 0.63 (95{\%} CI: 0.40 to 0.99) compared to use of non-CAD antihistamines (n = 304), and we found a tendencytowards a dose-response association. In our cell viability assay, we found consistent and dose-dependent cytotoxicity for all CAD but not non-CAD antihistamines. In this nationwide cohort study, use of antihistamines with CAD characteristics is associated with a prognostic benefit in ovarian cancer patients.",
author = "Freija Verdoodt and Christian Dehlendorff and Marja J{\"a}{\"a}ttel{\"a} and Robert Strauss and Anton Potteg{\aa}rd and Jesper Hallas and S{\o}ren Friis and Kjaer, {Susanne K}",
note = "{\circledC} The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2019",
month = "11",
day = "5",
doi = "10.1093/jnci/djz217",
language = "English",
journal = "National Cancer Institute. Journal (Print)",
issn = "0027-8874",
publisher = "Heinemann",

}

Antihistamines and ovarian cancer survival : nationwide cohort study and in vitro cell viability assay. / Verdoodt, Freija; Dehlendorff, Christian; Jäättelä, Marja; Strauss, Robert; Pottegård, Anton; Hallas, Jesper; Friis, Søren; Kjaer, Susanne K.

I: National Cancer Institute. Journal (Print), 05.11.2019.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Antihistamines and ovarian cancer survival

T2 - nationwide cohort study and in vitro cell viability assay

AU - Verdoodt, Freija

AU - Dehlendorff, Christian

AU - Jäättelä, Marja

AU - Strauss, Robert

AU - Pottegård, Anton

AU - Hallas, Jesper

AU - Friis, Søren

AU - Kjaer, Susanne K

N1 - © The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2019/11/5

Y1 - 2019/11/5

N2 - Antihistamines with cationic amphiphilic drug (CAD) characteristics induce cancer-specific cell death in experimental studies. Epidemiologic evidence is, however, limited. In a Danish nationwide cohort of ovarian cancer patients diagnosed during 2000-2015 (n = 5075), we evaluated the association between antihistamine prescriptions and cancer mortality. We used Cox regression models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for ovarian cancer mortality. In an in vitro cell viability assay, we evaluated cell-death in three ovarian cancer cell lines after treatment with clinically relevant doses of eight antihistamines. In our cohort study, CAD antihistamine use (≥1 prescription; n = 133) was associated with a HR of 0.63 (95% CI: 0.40 to 0.99) compared to use of non-CAD antihistamines (n = 304), and we found a tendencytowards a dose-response association. In our cell viability assay, we found consistent and dose-dependent cytotoxicity for all CAD but not non-CAD antihistamines. In this nationwide cohort study, use of antihistamines with CAD characteristics is associated with a prognostic benefit in ovarian cancer patients.

AB - Antihistamines with cationic amphiphilic drug (CAD) characteristics induce cancer-specific cell death in experimental studies. Epidemiologic evidence is, however, limited. In a Danish nationwide cohort of ovarian cancer patients diagnosed during 2000-2015 (n = 5075), we evaluated the association between antihistamine prescriptions and cancer mortality. We used Cox regression models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for ovarian cancer mortality. In an in vitro cell viability assay, we evaluated cell-death in three ovarian cancer cell lines after treatment with clinically relevant doses of eight antihistamines. In our cohort study, CAD antihistamine use (≥1 prescription; n = 133) was associated with a HR of 0.63 (95% CI: 0.40 to 0.99) compared to use of non-CAD antihistamines (n = 304), and we found a tendencytowards a dose-response association. In our cell viability assay, we found consistent and dose-dependent cytotoxicity for all CAD but not non-CAD antihistamines. In this nationwide cohort study, use of antihistamines with CAD characteristics is associated with a prognostic benefit in ovarian cancer patients.

U2 - 10.1093/jnci/djz217

DO - 10.1093/jnci/djz217

M3 - Journal article

JO - National Cancer Institute. Journal (Print)

JF - National Cancer Institute. Journal (Print)

SN - 0027-8874

ER -